\
&
Contact us
Published on | 2 weeks ago
ProgrammesThe Empowering Women in Agrifood (EWA) Advance Programme is designed to support advanced-stage women-led ventures in the agrifood sector. The programme aims to enhance participants' commercial and investment readiness, with applications open until 26 April 2026.
It will run from September to December 2026, offering tailored support including expert training, one-to-one mentoring, networking, and connections to investors and corporations. Up to ten selected entrepreneurs will engage in structured sessions that cover commercial strategy, investment readiness, and scaling.
Participants will also have the chance to present their businesses at a final Demo Day, where winners could receive prizes of up to 20.000 EUR to further enhance their growth.
This information is relevant to female entrepreneurs in the agrifood sector, particularly those looking to scale their startups. Additional details can be found on the EIT Food website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.